The computational study of the tautomerization of Carmustine drug in the biological system: DFT approach

Momeni Landi, Mahnoush; Ahmadi, Sayed Ali; Akhgar, Mohammad Reza; Ghazanfari, Dadkhoda

The computational study of the tautomerization of Carmustine drug in the biological system: DFT approach

Document Type : Original Research

Authors

Mahnoush Momeni Landi

sayed ali ahmadi

Mohammad Reza Akhgar

Dadkhoda Ghazanfari

Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran

Abstract

Tautomers are isomers of a molecule that exist in solution or in a cell. They are interchangeable forms because chemical bonds are rearranged many times spontaneously. This is different from chirality, where molecules are mirror images (or enantiomers) of each other. DFT method was carried out to study the tautomerization of the mechanism of carmustine as an anti-cancer drug. In the carmustine structure, two conformational tautomers were predicted and both two tautomer structures were demonstrated for considering the role of changing atoms in the conformation of carmustine. Relative energies obtained at the B3LYP/6-311G++ (d,p) , Aug-cc-pVDZ and 6-311++g(2d,2p) basis sets. The highest occupied molecular orbital (HOMO), The lowest unoccupied orbital (LUMO), and bandgap energy of structures were calculated. Electronics parameters were obtained. electrophilicity. Electronegativity, softness, and hardness for determining the reactivity of compounds in biological media. have been studied. According to the data, the structure of carmustine and two tautomer conformations are stable but T1 is more stable than the other one.

Keywords

DFT

carmustine

tautomer

electronic parameter

Anti-cancer

Subjects

Pharmaceutical Biotechnology

[1] Carter SK, Schabel Jr FM, Broder LE, Johnston TP (1973) 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: a review. In. Adv Cancer Res 16. Elsevier:273–332.
[2] Naghipur A, Ikonomou MG, Kebarle P, Lown JW (1990) Mechanism of action of (2-haloethyl) nitrosoureas on DNA: discrimination between alternative pathways of DNA base modification by 1, 3-bis (2-fluoroethyl)-1-nitrosourea by using specific deuterium labeling and identification of reaction products by HPLC/tandem mass spectrometry. J Am Chem Soc 112(8):3178–3187.
[3] Puyo S, Montaudon D, Pourquier P (2014) from old alkylating agents to new minor groove binders. Crit Rev Oncol Hematol 89(1):43–61.
[4] Bodell WJ (2003) Repair of DNA alkylation products formed in 9L cell lines treated with 1-(2-chloroethyl)-1-nitrosourea. Mutat Res/Fundam Mol Mechan Mutagen 522(1):85–92.
[5] Schabel JF (1976) Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 60(6):665–698.
[6] Miyagami M, Tsubokawa T, Tazoe M, Kagawa Y (1990) Intraarterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir 30(8):582–590.
[7] Bindra JS, Lednicer D (1993) Chronicles of drug discovery, vol 1. John Wiley & Sons, Hoboken.
[8] Boice Jr JD, Greene MH, Killen Jr JY, Ellenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni Jr JF (1983) Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309(18):1079–1084.
[9] Zackheim HS, Feldmann RJ, Lindsay C, Maibach HI (1977) Percutaneous absorption of I, 3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. Br J Dermatol 97(1):65–67.
[10] WalkerMD, Alexander Jr E, HuntWE, MacCarty CS,Mahaley JrMS, Mealey Jr J, Norrell HA, Owens G, Ransohoff J, Wilson CB (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 49(3):333–343.
[11] Walker MD, Green SB, Byar DP, Alexander Jr E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303(23):1323–1329.
[12] Ludlum DB (1997), The chloroethy lnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Investig 15(6):588–598.
[13] Zhuang L, Gao J, Zeng Y, Yu F, Zhang B, LiM, Derendorf H, Liu C (2011) HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposomeencapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. Eur J Drug Metab Pharmacokinet 36(2):61–69.
[14] Kramer RA, Boyd MR, Dees JH (1986) Comparative nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) and chlorozotocin: functional-structural correlations in the Fischer 344 rat. Toxicol Appl Pharmacol 82(3):540–550.
[15] Drabløs F, Feyzi E, Aas PA, Vaagbø CB, Kavli B, Bratlie MS, Peña-Diaz J, Otterlei M, Slupphaug G, Krokan HE (2004) Alkylation damage in DNA and RNA—repair mechanisms and medical significance. DNA repair 3(11):1389–1407.
[16] Ducastelle T, Raguenez-Viotte G, Fouin-Fortunet H, Matysiak M, Hemet J, Fillastre J (1988) The hepatotoxicity of 1-(2-chloroethyl)- 3-cyclohexyl-1-nitrosourea (CCNU) in rats. Cancer Chemother Pharmacol 22(2):153–162.
[17] Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM, Moore AS (2004) Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 18(1):75–80.
[18] Wheeler GP, Chumley S (1967) Alkylating activity of 1, 3-bis (2- chloroethyl)-1-nitrosourea and related compounds. J Med Chem 10(2):259–261.
[19] Barranco S, Humphrey R (1971), The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro. Cancer Res 31(9):1218–1223.
[20] Bhuyan B, Scheidt L, Fraser T (1972) Cell cycle phase specificity of antitumor agents. Cancer Res 32(2):398–407.
[21] Tobey RA, Crissman HA (1975) Comparative effects of three nitrosourea derivatives on mammalian cell cycle progression. Cancer Res 35(2):460–470.
[22] Le Blanc GA,Waxman DJ (1989) Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metab Rev 20(2–4):395–439.
[23] Lemoine A, Lucas C, Ings R (1991) Metabolism of the chloroethy lnitrosoureas. Xenobiotica 21(6):775–791.
[24] Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH (2013) Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals 6(12):1475–1506.
[25] Pratt WB, Ensminger WD, Ruddon RW (1994), The anticancer drugs. Oxford University Press, USA.
[26] GESMJ, F.; Trucks, G.W.; Schlegel, H.B.; Robb, B.M.M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; HPHGA, P.; Nakatsuji, H.; Caricato, M.; Li, X.; Gaussian 09. Revision A, 2 , 2009.